DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
In Vivo Validation of Cell of Origin and Candidate Drivers of Group 4 Medulloblastoma
[Technical Report, Annual Report]
CALIFORNIA UNIV REGENTS SAN FRANCISCO
Pagination or Media Count:
Medulloblastoma is the most common childhood brain tumor and is a major cause of cancer related mortality in children. Although current treatment strategies reach a 60-80 percent 5-year survival rate, a proportion of cases remain unresponsive to therapy and lack more effective treatment options. A significant molecular heterogeneity exists within the medulloblastoma subgroups, especially within Group 4 medulloblastoma G4-MB, challenging the choice and prediction of response to a particular therapy. Our objective is to define the cell-of-origin and candidate drivers of G4-MB, and to develop pre-clinical mouse models that reflect G4-MB tumorigenesis. We have developed a tumor mouse model that allows us to manipulate early iPSC-derived neuroepithelial stem cells, a cell population suggested as the cell-of-origin for but not limited to G4-MB. Using this model we have shown that the G4-MB candidate drivers SRC and ERBB4 induce tumor formation in TP53WT and TP53mutNESCs. Furthermore we are testing pre-clinical therapies of SRC inhibition in our SRC-ERBB4 tumor-bearing mice and are exploring other genetic G4-MB drivers such as ZMYM3. Our mouse models established here will decipher the yet unknown origin of Group 4 medulloblastoma and inform about basic principles of tumorigenesis in the brain.
[A, Approved For Public Release]